For #TrialTuesday , .Gopa Iyer Memorial Sloan Kettering Cancer Center leads Alliance for Clinical Trials in Oncology trial A031701 to see how well gemcitabine hydrochloride and cisplatin work in treating patients with invasive #bladder #urothelial #cancer . Learn more: bit.ly/AllianceA031701 #NCI #NCTN #blcsm Bladder Cancer Advocacy Network

#gupath

Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. Journal of Clinical Oncology Robert Motzer MD Memorial Sloan Kettering Cancer Center ascopubs.org/doi/abs/10.120…

Please join me in welcoming Nima Almassi to the urology staff Cleveland Clinic Urology. Dr. Almassi is returning back to the GUKI family after completing a Urologic Oncology fellowship @sloan_kettering. Nima, we are all very excited to be welcoming you back.

Sia Daneshmand, M.D. Peter Black Gary Steinberg Ashish M. Kamat, MD, MBBS Bladder Cancer Advocacy Network @gorejohn This remains a real concern as we move attempts at bladder preservation ahead. 5% not insignificant! Can DDR mutations in primary predict for complete nodal response as well? TBD. Gopa Iyer NCT03609216 trial should be supported. @sloan_kettering UrologyMSK

Excited to open Neoadjuvant trial of dd Gem-Cis in #MIBC with bladder sparing option for pts with select genetic alterations led by Gopa Iyer Alliance for Clinical Trials in Oncology Jonathan Rosenberg MD Michael Morris
Cleveland Clinic MD Cleveland Clinic Urology Omar Mian Bladder Cancer Advocacy Network

clinicaltrials.gov/ct2/show/NCT03…